On Friday, Adma Biologics Inc (NASDAQ: ADMA) opened higher 0.61% from the last session, before settling in for the closing price of $13.08. Price fluctuations for ADMA have ranged from $3.06 to $14.03 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 73.26% over the last five years. Company’s average yearly earnings per share was noted 371.15% at the time writing. With a float of $223.89 million, this company’s outstanding shares have now reached $226.06 million.
The firm has a total of 624 workers. Let’s measure their productivity.
Adma Biologics Inc (ADMA) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Adma Biologics Inc is 3.41%, while institutional ownership is 75.79%. The most recent insider transaction that took place on Jun 14 ’24, was worth 1,071,980. In this transaction President,CEO, and Interim CFO of this company sold 100,000 shares at a rate of $10.72, taking the stock ownership to the 2,081,475 shares. Before that another transaction happened on Mar 19 ’24, when Company’s Director sold 411,829 for $6.08, making the entire transaction worth $2,503,920. This insider now owns 2,115,671 shares in total.
Adma Biologics Inc (ADMA) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 3/31/2024, the company posted -0.03 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -0.02) by -0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.09 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 371.15% per share during the next fiscal year.
Adma Biologics Inc (NASDAQ: ADMA) Trading Performance Indicators
Check out the current performance indicators for Adma Biologics Inc (ADMA). In the past quarter, the stock posted a quick ratio of 1.86. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.77. Likewise, its price to free cash flow for the trailing twelve months is 189.13.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.02, a number that is poised to hit 0.08 in the next quarter and is forecasted to reach 0.54 in one year’s time.
Technical Analysis of Adma Biologics Inc (ADMA)
Analysing the last 5-days average volume posted by the [Adma Biologics Inc, ADMA], we can find that recorded value of 3.01 million was better than the volume posted last year of 2.88 million. As of the previous 9 days, the stock’s Stochastic %D was 38.77%. Additionally, its Average True Range was 0.45.
During the past 100 days, Adma Biologics Inc’s (ADMA) raw stochastic average was set at 89.57%, which indicates a significant increase from 61.84% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 39.68% in the past 14 days, which was lower than the 48.89% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $11.12, while its 200-day Moving Average is $6.58. Now, the first resistance to watch is $13.36. This is followed by the second major resistance level at $13.56. The third major resistance level sits at $13.77. If the price goes on to break the first support level at $12.95, it is likely to go to the next support level at $12.74. Now, if the price goes above the second support level, the third support stands at $12.54.
Adma Biologics Inc (NASDAQ: ADMA) Key Stats
There are currently 231,809K shares outstanding in the company with a market cap of 3.05 billion. Presently, the company’s annual sales total 258,220 K according to its annual income of -28,240 K. Last quarter, the company’s sales amounted to 81,880 K and its income totaled 17,810 K.
